Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.com

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report released on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

NASDAQ:TTNP opened at $3.86 on Monday. The company has a 50-day moving average of $4.50 and a 200-day moving average of $5.53. Titan Pharmaceuticals has a twelve month low of $3.51 and a twelve month high of $14.80.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.